Adherence to methotrexate in juvenile idiopathic arthritis.
Non-adherence to treatments for chronic diseases may jeopardize patients' health, increase costs of care, and cause unnecessary clinic appointments and diagnostic studies, as well as additional treatments with potentially serious side effects. Little is known about adherence to methotrexate in pediatric rheumatology. Because this medication is commonly used in JIA, we assessed adherence among children receiving methotrexate in two countries. A total of 76 outpatients (M:F 21:55) with JIA seen in Rio de Janeiro (Brazil) and in Boston (US) taking methotrexate for >2 months were enrolled. Questionnaires were completed by the parents from both centers. Non-adherence was defined as omission of ≥3 prescribed doses in the previous 8 weeks. Patients' ages ranged from 1 to 17 years. Mean time on methotrexate was 20.5 months (±25). Overall rate of non-adherence was 18%. The rate of reported non-adherence was 8% in Boston and 24% in Rio de Janeiro (P = 0.012). The main reason for non-adherence in Boston was "child refused"; in Rio de Janeiro, the main reason was inability to obtain medication. Age had a negative association with adherence (P < 0.0001). Sex, time on methotrexate, route of administration, or concomitant use of other medications were not associated with adherence. Eighteen percent of children with JIA prescribed methotrexate were non-compliant. The difference in reasons for poor adherence between patients in Rio de Janeiro and Boston suggests that different strategies may be needed to improve adherence in these 2 settings. The rate of non-adherence warrants further investigation.
Division of Pediatric Rheumatology, Floating Hospital For Children at Tufts Medical Center, 800 Washington St, Box# 190, Boston, MA 02148, USA. cpelajo@tuftsmedicalcenter.org
Christina F
CF
Pelajo
Caitlin M
CM
Sgarlat
Jorge M
JM
Lopez-Benitez
Sheila K F
SK
Oliveira
Marta C F
MC
Rodrigues
Flavio R
FR
Sztajnbok
Christianne C
CC
Diniz
Laurie C
LC
Miller
D000293:Adolescent; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D002652:Child Behavior / Q000523:psychology; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D055118:Medication Adherence / Q000523:psychology; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects
D018501:Antirheumatic Agents; D008727:Methotrexate
Br J Rheumatol. 1997 Nov;36(11):1218-23
9402869
Pediatr Ann. 2002 Jun;31(6):373-9
12073741
Arthritis Rheum. 2005 Dec 15;53(6):905-10
16342104
Pediatr Rheumatol Online J. 2007 May 18;5:10
17550635
Arch Dis Child. 2003 Mar;88(3):197-200
12598376
Arch Phys Med Rehabil. 1988 Jun;69(6):439-41
3377670
Health Psychol. 2002 Nov;21(6):620-3
12433016
Arthritis Rheum. 2009 Jan 15;61(1):46-51
19116975
Am J Dis Child. 1981 May;135(5):434-6
7234770
Arthritis Rheum. 2007 Mar 15;57(2):226-33
17330298
JAMA. 2002 Dec 11;288(22):2868-79
12472329
Arthritis Rheum. 2006 Aug 15;55(4):558-63
16874776
Arch Phys Med Rehabil. 1984 May;65(5):267-9
6712455
Scand J Rheumatol. 1999;28(1):10-8
10092159
Arthritis Care Res. 1999 Oct;12(5):314-24
11081000